Considering the current target drugs availability and current evidence, ESMO recommends routine use of NGS on tumour samples in advanced NSCLC, including ALK, BRAF, EGFR, ERBB2, KRAS, MET, NTRK, RET and ROS1 genes [109, 110]. Here, RET is linked to neoplasm.